首页 | 本学科首页   官方微博 | 高级检索  
     

微波消融术联合肝动脉介入栓塞术治疗肝细胞癌的临床研究
引用本文:马玫丽,盛立军,任国华,宋鹏远. 微波消融术联合肝动脉介入栓塞术治疗肝细胞癌的临床研究[J]. 现代肿瘤医学, 2014, 0(10): 2396-2400
作者姓名:马玫丽  盛立军  任国华  宋鹏远
作者单位:1. 青岛市市立医院,山东 青岛,266011
2. 山东省医学科学院附属医院内五科,山东 济南,250031
摘    要:目的:比较微波消融术( microwave ablation,MWA)联合或者不联合经肝动脉化疗栓塞术( transcathe-ter arterial chemoembolization,TACE)治疗肝细胞癌( HCC)的临床疗效以及不良反应。方法:选择89例2006年10月至2009年7月入我院治疗的肿瘤直径≤5cm的原发性肝细胞癌患者,采用随机数字法分为MWA联合TACE组(n=44)或者单独MWA组(n=45)进行随机对照研究,观察两组患者的总生存率(OS)、无复发生存率( RFS)以及不良反应。结果:所有患者均治疗成功,随访时间为7-62个月,随访结束时联合组患者死亡15人,微波组死亡23人。联合组、微波组分别有16人、25人出现疾病进展。1年、2年、3年OS分别为86.4%,74.4%,61.8%和77.4%,63.6%,50.0%。对应的RFS为72.4%,61.6%,45.8%和61.7%,52.2%,39.8%。联合组的OS以及RFS高于单纯微波组(风险比率HR为0.323,95%CI为0.295-0.351,P=0.002;风险比率HR为0.258,95%CI为0.230-0.286,P=0.02)。研究过程中无治疗相关性死亡。对相关因素进行Logistic回归分析,治疗分配、肿瘤大小、肿瘤数目是OS相关预后因素,治疗分配、肿瘤大小是RFS相关预后因子。结论:MWA联合TACE术治疗病灶≤5cm的HCC患者疗效优于单独的MWA治疗疗效。

关 键 词:肝细胞癌  微波消融术  介入栓塞术  联合

Clinical research of microwave ablation plus transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma
Ma Meili,Sheng Lijun,Ren Guohua,Song Pengyuan. Clinical research of microwave ablation plus transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma[J]. Journal of Modern Oncology, 2014, 0(10): 2396-2400
Authors:Ma Meili  Sheng Lijun  Ren Guohua  Song Pengyuan
Affiliation:Ma Meili, Sheng Lijun, Ren Guohua, Song Pengyuan (1Qingdao Municipal Hospital, Shandong Qingdao 266011, China;2 The Fifth Medical Department,Affiliated Hospital of Shandong Acade- my of Medical Sciences, Shandong Jinan 250031, China.)
Abstract:Objective:To compare microwave ablation( MWA)with or without transcatheter arterial chemoemboli-zation( TACE)in the treatment of hepatocellular carcinoma( HCC). Methods:The research was conducted on 89 pa-tients with HCC less than 5cm received treatment in our hospital between October 2006 and July 2009. They were ran-domly assigned to recesive MWA combined with TACE(n=44)or MWA alone(n=45). The end point were overall survival( OS)、recurrence-free( RFS)and adverseeffects. Results:Technical success was achieved in all patients,at a follow-up of 7 to 62 months,15 patients in the MWA-TACE group and 23 patients in the MWA group had died. 16 patients and 25 patients had developed recurrence in the MWA-TACE group and MWA group,respectively. The 1-,2-,and3-year overall survivals for the MWA-TACE group and the MWA group were 86. 4%,74. 4%,61. 8% and 77. 4%,63. 6%,50. 0%,respectively. The corresponding recurrence-free survival were 72. 4%,61. 6%,45. 8%and 61. 7%,52. 2%,39. 8%. Patients in the MWA-TACE group had better overall survival and recurrence - free survival than patients in the MWA group( hazard ratio ,0. 323;95%CI:0. 295 to 0. 351;P=0. 002;hazard ratio, 0. 258;95%CI:0. 230 to 0. 286;P=0. 02). There were no treatment-related deaths. On Logistic regression analy-ses,treatment allocation and tumor size were significant prognostic factors for recurrence-free survival. Conclusion:MWA-TACE was superior to MWA alone in improving survival for patients with HCC less than 5cm.
Keywords:hepatocellular carcinoma( HCC)  microwave ablation( MWA)  transcatheter arterial chemoembolization ( TACE)  combination
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号